OMUFA FY2026 fee rates and deadlines: what OTC sites must act on

For OTC monograph drug facility operators, the payment window for FY 2026 OMUFA user fees is not a calendar formality, missing it triggers statutory penalties that FDA is empowered to enforce under the Continuing Appropriations Act, 2026. CDER's Division of User Fee Management has scheduled a structured briefing to walk facility heads and regulatory affairs leads through every operational element before the liability period closes.

FDA's CDER schedules OMUFA FY2026 fee briefing for industry

On May 5, 2026, CDER's Small Business and Industry Assistance (SBIA) programme hosted a one-hour webinar covering the full scope of Over-the-Counter Monograph Drug User Fee Amendments obligations for fiscal year 2026. Speakers Tramara Dam, Pharm.D., MBA, and Madeline Faunce, Branch Chief of the Policy and Operations Branch within the Division of User Fee Management, led the session on behalf of the Office of Finance, Budget, and Acquisitions.

The session addressed fee types, FY 2026 target revenue figures, applicable timelines, the facility registration process, the fee payment portal workflow, refund eligibility criteria, and the penalty structure associated with non-payment. The statutory authority sits in title V of Division F of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, with programme performance goals governed by the OMUFA II Commitment Letter covering fiscal years 2026 through 2030.

Where regulatory affairs and plant operations share the compliance burden

The registration requirement for OTC monograph drug facilities is a distinct obligation from product-level fee liability, both carry independent deadlines, and misalignment between site registration status and fee payment records is a documented source of penalty exposure. Regulatory affairs leads managing monograph order requests and plant heads overseeing manufacturing operations need coordinated visibility into the same fee liable period to avoid gaps.

The webinar's intended audience reflects that dual accountability: the session was designed for regulatory affairs professionals, facility operators, importers, supply-chain leads, and consultants working across the processing, manufacturing, and development of non-prescription monograph products. For sites with foreign manufacturing or import dependencies, the OMUFA registration and payment obligations extend to the importer of record, adding a supply-chain compliance layer that procurement and logistics teams should be tracking alongside RA.

Read against the OMUFA II Commitment Letter performance framework, the FY 2026 fee cycle is the first full fiscal year under the renewed five-year programme structure. That means the fee rates and revenue targets set now establish the baseline against which CDER will measure programme adequacy through FY 2030, making accurate facility registration and timely payment operationally significant beyond the immediate fiscal year.

The OMUFA II programme window and the next fee cycle checkpoint

The OMUFA II Commitment Letter, which governs performance goals and procedures from FY 2026 through FY 2030, sets the multi-year framework within which annual fee rates will be recalibrated. Facility operators should treat each annual payment cycle as a data point in that longer compliance arc rather than a standalone obligation.

CDER's draft guidance titled "Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program," published November 2, 2022, remains the primary interpretive reference for fee assessment methodology. Sites that have not reconciled their facility registration records against that guidance ahead of the FY 2026 liable period should prioritise that review. The FDA User Fees Payment Portal and the OMUFA Cover Sheet are the operative submission instruments; both were referenced in the May 5 session as part of the payment process walkthrough.

The next structured opportunity to clarify fee assessment questions will likely align with CDER's annual OMUFA programme review, which feeds into the FY 2027 rate-setting process under the OMUFA II commitment framework.